The impacts of probiotics in eradication therapy of Helicobacter pylori

被引:0
作者
Xiaofen Bai
Minjie Zhu
Yajun He
Tengyan Wang
Da Tian
Jianchang Shu
机构
[1] Guangzhou Red Cross Hospital,Department of Gastroenterology
[2] Jinan University,Department of Clinic Laboratory
[3] Guangzhou Red Cross Hospital,Department of Gastroenterology
[4] Jinan University,undefined
[5] Guangzhou Panyu Central Hospital,undefined
来源
Archives of Microbiology | 2022年 / 204卷
关键词
Probiotics; Eradication therapy; Helicobacter pylori;
D O I
暂无
中图分类号
学科分类号
摘要
Helicobacter pylori (H. pylori) is a well-known pathogen that infects approximately half of the world’s population. It is a pathogenic agent with potential health hazards related to diverse diseases, especially digestive diseases, such as chronic gastritis, peptic ulcer, and gastric carcinoma. In clinical, antibiotics are commonly applied in eradication therapy of H. pylori. However, the increase in antibiotic resistance and side effects has induced the failure of eradication therapy. Recent studies have shown that probiotic supplementation has promising application prospects. It can restore the gastrointestinal microbiota balance and prevent dysbacteriosis caused by antibiotics. Furthermore, it has been reported to have direct or indirect inhibitory effects on H. pylori. Probiotics may have a beneficial effect on H. pylori eradication. However, the strain, dosages, duration times, and safety of probiotic supplementation need further study before clinical applications.
引用
收藏
相关论文
共 389 条
[41]  
Oh CH(2016)Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study[J] Vojnosanit Pregl 289 337-289
[42]  
Chen YH(2014)Human trefoil factor 2 is a lectin that binds alpha-GlcNAc-capped mucin glycans with antibiotic activity against Helicobacter pylori[J] J Biol Chem 94 506-182
[43]  
Tsai WH(2015)Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial[J] Medicine 21 10644-677
[44]  
Wu HY(2016)Imbalance of Gastrointestinal Microbiota in the Pathogenesis of Helicobacter pylori-Associated Diseases[J] Helicobacter 11 420-161
[45]  
Chey WD(2014)Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J] Nat Rev Gastroenterol Hepatol 21 1146-1120
[46]  
Leontiadis GI(2015)Are probiotics useful in Helicobacter pylori eradication?[J] World J Gastroenterol 153 168-83
[47]  
Howden CW(2017)Global Prevalence of Helicobacter pylori Infection: systematic review and meta-analysis[J] Gastroenterology 62 762-149
[48]  
Chotivitayatarakorn P(2017)Primary Antibiotic Resistance of Helicobacter pylori in China[J] Dig Dis Sci 7 1906-1090
[49]  
Mahachai V(2017)Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance[J] Front Cell Infect Microbiol 15 1136-2
[50]  
Vilaichone RK(2014)Therapeutic modulation of gut microbiota: current clinical applications and future perspectives[J] Curr Drug Targets 65 731-30